MediPharm Labs Corp.
MEDIF
$0.0554
-$0.0046-7.67%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.83% | 3.89% | 28.18% | 13.29% | 6.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.83% | 3.89% | 28.18% | 13.29% | 6.03% |
| Cost of Revenue | 23.24% | -9.14% | 76.79% | 55.83% | -24.17% |
| Gross Profit | -6.85% | 34.56% | -18.87% | -27.31% | 329.68% |
| SG&A Expenses | 19.43% | -31.07% | 30.95% | -14.24% | -27.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -334.02% | 16.16% | -324.50% | 558.23% | -84.21% |
| Total Operating Expenses | 20.64% | -19.67% | 53.06% | 16.74% | -26.47% |
| Operating Income | -54.15% | 87.79% | -130.36% | -31.99% | 68.24% |
| Income Before Tax | -44.34% | 89.93% | 45.18% | 37.00% | 11.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.34% | 89.93% | 39.81% | 36.96% | 11.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.34% | 89.93% | 39.81% | 36.96% | 11.98% |
| EBIT | -54.15% | 87.79% | -130.36% | -31.99% | 68.24% |
| EBITDA | -97.04% | 99.17% | -91.68% | -55.40% | 75.61% |
| EPS Basic | -40.43% | 90.91% | 44.44% | 39.51% | 14.55% |
| Normalized Basic EPS | -51.85% | 89.47% | -111.11% | -15.38% | 70.00% |
| EPS Diluted | -40.43% | 90.91% | 44.44% | 39.51% | 14.55% |
| Normalized Diluted EPS | -51.85% | 89.47% | -111.11% | -15.38% | 70.00% |
| Average Basic Shares Outstanding | 2.61% | 2.83% | 9.01% | 3.15% | 4.26% |
| Average Diluted Shares Outstanding | 2.61% | 2.83% | 9.01% | 3.15% | 4.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |